Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating…
USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods of use claims involving new…
No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of StudyDSMB Recommendation Allows for…
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on…
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE…
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)…
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most…
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients…
VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…
Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital…